Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2018-07-16

Clinical Trial Update: A Phase Ib Study of NVX-508 in Sickle Cell Disease [Phase 1]

View source ↗

Summary

The Phase Ib trial of NVX-508 in sickle cell disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NVX-508

Snippet

Sponsor: Amma Owusu-Ansah, MD | Conditions: Sickle Cell Disease | Phase 1 | Status: WITHDRAWN